Dr. Nik Bhandari

About

Dr Bhandari works in assessing and treating Neurocognitive disorders such as various types of Dementia and Delirium.

The types of Neuropsychiatric illnesses treated include psychiatric sequelae of head injury, Stroke, Huntington’s disease, Alcohol Related Brain Damage, and Parkinson’s Psychosis. He also treats functional mental health disorders in later life, such as Depression, Anxiety, and Psychosis (including schizophrenia and paraphrenia).

Languages spoken: English, Hindi, Punjabi

Education:

• Dec 2014 MSc Clinical Neuropsychiatry, University of Birmingham, UK.
• Aug 2014 Certificate of Completion of Training (CCT), Old Age Psychiatry, Royal College of Psychiatrists, UK.
• Aug 2014 Approved Clinician, Mental Health Act 1983 (England) (Renewed 2018) South-West Division, Royal College of Psychiatrists, UK.
• Aug 2014 DoLS Mental Health Assessor (Renewed yearly) Mental Capacity Act 2005
• Jul 2008 Member of the Royal College of Psychiatrists, UK.
• Dec 2001 MBBS, Government Medical College, Amritsar, India. Baba Farid University of Health Sciences, India.

Career History:

Sep 22 onwards Locum Consultant Psychiatrist for Old Age Services, Avon Wiltshire NHS Trust, UK.

Mar 15 – Sep 22 Consultant Psychiatrist for Old Age Services, Gloucestershire Health and Care NHS Foundation Trust, UK.

Dec 14 – Feb 15 Locum Consultant Psychiatrist for Old Age Services, Leicestershire Partnership NHS Trust, UK.

Aug 11 – Oct 14 Psychiatry Registrar, Specialist Training in Old Age Psychiatry, Royal College of Psychiatrists, UK.

Apr 09 – Jul 11 Specialty Doctor, Old Age Psychiatry.

Oct 04 – Feb 09 Psychiatry Registrar, Core Specialist Training, Royal College of Psychiatrists, UK

Jul 03 – Feb 04 House Officer, General Surgery, DMC Hospital, Ludhiana, India.

Jan 02 – Dec 02 Internship (Foundation years), Baba Farid University of Health Sciences, India.

Research Experience:

Aug 2020 – Sep 21 Chief Investigator for a Phase II multicentre Randomised Controlled Trial (RCT) looking into the efficacy and safety of a Disease Modifying Treatment (DMT) for Alzheimer’s disease.

2019 – Sep 21 Principal Investigator for two Phase III multicentre trials for a monoclonal antibody-based DMT for Alzheimer’s disease.

2017 – 2019 Principal Investigator for a Phase III multicentre RCT looking into an IV infusion-based DMT for Alzheimer’s disease.

2014 – 2015 Led Cochrane project on Pharmacological management of Frontotemporal Dementia. The systematic review had to be abandoned after the initial approval of the project due to time and resource issues.

Associations:

Member of the Royal College of Psychiatrists, UK